We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.00 | -0.51% | 1,356.50 | 1,356.00 | 1,356.50 | 1,370.00 | 1,353.00 | 1,365.00 | 5,013,886 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.41 | 56.52B |
From Jan 2020 to Jan 2025
By Jaime Llinares Taboada
GlaxoSmithKline PLC said Friday that it has entered into a collaboration with Alector Inc. for the development and commercialization of two clinical stage monoclonal antibodies for neurodegenerative diseases.
The London-listed healthcare company said that Alector will receive $700 million in upfront payments and might receive an additional $1.5 billion in clinical development, regulatory and commercial launch-related milestone payments.
GSK said enrolment is currently underway for a Phase 3 trial for the AL001 antibodies, while AL101 is in Phase 1a clinical trial.
Both companies have agreed to co-commercialize and share profits in the U.S. GSK will retain exclusive commercialization rights outside the U.S.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
July 02, 2021 08:08 ET (12:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
